XML 51 R37.htm IDEA: XBRL DOCUMENT v3.20.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2020
Accounts Receivable [Member]    
Product Information [Line Items]    
Concentration risk percentage   10.00%
Regenerative Medicine Product Segment [Member] | Revenue Benchmark [Member]    
Product Information [Line Items]    
Concentration risk percentage 55.00% 33.00%
COVID-19 Testing [Member] | Revenue Benchmark [Member]    
Product Information [Line Items]    
Concentration risk percentage 94.00% 96.00%
COVID-19 Testing [Member] | Accounts Receivable [Member]    
Product Information [Line Items]    
Concentration risk percentage   40.00%